Purpose of review The pathogenesis of lung cancer and pulmonary fibrotic disorders partially overlaps. This review focuses on the common features of the two disease categories, aimed at advancing our translational understanding of their pathobiology and at fostering the development of new therapies.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progressive age-related and smoking-related diffuse parenchymal lung disease believed to result from chronic alveolar epithelial cell injury and defective repair in response to yet unknown environmental insults [1] . IPF culminates from perpetual proliferation and migration of mesenchymal cells and from formation of fibroblast foci, in which activated myofibroblasts secrete increased amounts of extracellular matrix (ECM) leading to remodeling and distortion of pulmonary structure and function [2] . The disease is rare, but its incidence increases worldwide [3 & ]. Moreover, IPF unequivocally leads to death within 2-5 years after diagnosis and there is no effective etiologic cure, a fact that underlines the need for novel approaches [4,5 & ,6 ]. Lung cancer is the leading cause of cancerrelated death in men and women worldwide [7 & ]. This age-related and smoking-related tumor results from chronic exposure of the airway and alveolar epithelium to environmental smoke leading to repetitive cycles of mutagenesis, apoptosis, defective DNA repair, mutation persistence, progressive hyperplasia and dysplasia, and frank lung occupation and dissemination [8] . Similar to IPF, death usually ensues within few years after diagnosis despite targeted therapies [9] .
Several studies have highlighted the clinical risk factors associated with lung cancer development in IPF patients and examined the clinical characteristics and survival of patients having both IPF and lung cancer [10] [11] [12] [13] [14] [15] 16 Upon injury, epithelial cells interact with mesenchymal cells and the ECM, promoting the progression of fibrosis [27, 28] . In a similar pattern, tumors behave like open wounds and activated mesenchymal cells are implicated in the pathobiology of both fibrosis and cancer [29] . The continuous process of tumorigenesis is characterized by evasion of cell death, sustained proliferative signaling, evading growth suppressors, enabling replicative immortality, activating invasion and metastasis and tumor-promoting inflammation, among other features, but most strikingly by unremitted growth and development of tumor niches supported by their interactions with stromal cells and the tumor microenvironment [30, 31] . Alike tumor-initiated tissues, fibrotic tissues are composed of epithelial cells and fibroblasts/mesenchymal cells in close interaction with immune cells, angiogenic factors and the ECM [30, 32] .
APOPTOSIS
As opposed to normal wound repair, scar myofibroblasts escape apoptosis like cancer cells [33] [34] [35] [36] [37] [38] and can be restrained upon inhibition of antiapoptotic signaling pathways [39] [40] [41] [42] [43] [44] . The mechanisms involved in mesenchymal cell resistance to apoptosis during IPF are multiple and not fully understood [33, 34, [41] [42] [43] [45] [46] [47] . Apoptosis may be mediated by two pathways. The extrinsic pathway promotes apoptosis by stimulation of members of the tumor necrosis factor receptor family, and the intrinsic pathway induces apoptosis by certain cellular stressors such as DNA damage or growth factor inhibition. Along the extrinsic pathway, death receptors like Fas are implicated in lung fibrosis both by enforcement of epithelial cell apoptosis during the injurious phase and through resistance of fibroblasts to Fas-induced apoptosis during the resolution of lung injury. The Fas/Fas ligand (FasL) pathway is important in the attenuation of lung fibroblast survival during lung repair and fibrosis [47] [48] [49] . The expression of FasL by lung fibroblasts during IPF leads to continuous epithelial cell apoptosis and cell death escape by immune surveillance [50, 51] which can be reversed because of the low expression of Fas from fibrotic lung fibroblasts [52, 53] . Furthermore, lung fibroblasts express c-FLIP [cellular Fas-associated protein with death domainlike interleukin (IL)-1b-converting enzyme-inhibitory protein], which represses apoptotic signals downstream of Fas [47] . In addition, IL-6, a cytokine known to be involved in repair and remodeling, inhibits apoptosis and induces expression of the antiapoptopic protein B-cell lymphoma 2 (Bcl-2) in fibroblasts of patients with IPF who also exhibit inhibition of the mitochondrial depolarization that is a critical component in the apoptotic program [41, 54] . Finally, IPF fibroblasts overexpress IAP proteins, which can inhibit apoptosis via blockade of caspase activation [41, 44, 46, 47] . In both tumorigenesis and fibrosis, interplay with the ECM is important for apoptosis evasion [55] [56] [57] [58] [59] [60] . Mechanical forces influence several biological processes, which involve cell adhesion and ECM organization where proteins and protein kinases have a critical role. Interactions such as PTEN (protein phosphatase and tensin homologue) suppression, phosphatidylinositol 3-kinase (PI3K) negative regulation and protein kinase B (AKT) activation are capital for antiapoptosis [56, 61] . Hippo and its interplay with transforming growth factor (TGF)-b are also a key regulator of ECM remodeling and cell differentiation and are implicated in both lung fibrosis and cancer development through protumor phenomena like apoptosis resistance [60] . Moreover, cell culture substrates that recapitulate the stiffness of fibrotic lungs are sufficient to decrease fibroblast apoptosis and increase prosurvival BCL-2 expression [41, 57, 62] . TGF-b1 also promotes myocardin-related transcription factor-A (MRTF-A) nuclear localization where as a transcriptional coactivator of serum response factor it regulates myofibroblast differentiation and survival, further promoting lung fibrosis [41, 42, 62, 63] . MRTF-A has also been targeted as a partner of tumor progression and metastasis [64] [65] [66] . Apart from the ECM, several apoptosis signaling pathways are directly linked to fibrosis and malignancies. Protein kinases such as AKT (also known as protein kinase B) and FAK (focal adhesion kinase) known for their active role in a variety of tumors are also activated by profibrotic KEY POINTS mediators like TGF-b1 and endothelin-1 in lung fibrosis [67] [68] [69] [70] [71] [72] . These kinases induce the expression of downstream partners like IAP family members that are highly expressed in fibrotic lung fibroblasts and have also been shown to play a crucial role in cancer as they promote apoptosis escape [34, 44, 46, 67, [73] [74] [75] .
CELLULAR PROLIFERATION
Another characteristic of malignant cells is their perpetual proliferative signaling which has also been described in fibrotic lung fibroblasts and represents a mechanistic similarity between the two diseases. In patients with IPF, lung fibroblasts display high and heterogenic proliferative properties [76] . Although signals that enhance cell proliferation are reported in the pathogenesis of lung fibrosis in humans and murine models, the exact mechanisms by which this event is promoted are not yet fully understood. Several protein kinases, well known for their multifaceted role in malignancies, such as the receptors for vascular endothelial growth factor, platelet-derived growth factor and fibroblast growth factor (FGF), were recently implicated in sustained proliferation of pulmonary fibro-
Moreover, TGF-b1, endothelin-1 and ECM ligation of cell-surface integrins activate the PI3K/AKT pathway which is highly observed in the IPF fibroblastic foci [68, [78] [79] [80] . PI3K/AKT activation induced by b1-integrin urges fibroblasts to abjure the antiproliferative signals [81] . Furthermore, inhibition of its signaling reduces lung fibroblast proliferation and fibrosis development both in vitro and in vivo [82] [83] [84] [85] [86] . Anticancer treatments have been shown to act suppressive in IPF patients, further amplifying the various consequences of proliferating signaling [87] [88] [89] . In addition, lung fibroblasts have been shown to abjure mediators for growth suppression, a main characteristic of malignant cells. IPF fibroblasts resist signals like prostaglandin (PG)E2, which inhibits proliferation and differentiation while enhancing susceptibility to apoptosis in normal lung fibroblasts or polymerized collagen growth [81, 90] .
AGING
As noted above, age is highly related to lung diseases and is a risk factor for IPF and also for various cancers, but the mechanisms by which age contributes to each disease differ [91, 92] . Chromosome replication ageing is crucial for malignancies and as recently reported for IPF fibroblasts [39] . In contrast to cancer cells, wherein the enhanced telomerase activity lengthens telomeres and contributes to continuous cell proliferation, fibrotic lung fibroblasts exhibit accelerated telomere shortening and impaired telomerase function [93] . As a result, both increased fibrosis and decreased fibroblast apoptosis occur and predispose poor survival for patients with IPF [94] [95] [96] [97] [98] .
INVASION AND METASTASIS
One important hallmark of cancer is the ability to invade and metastasize. Among others, matrix metalloproteases are strongly related to invasion and migration of cells, as well as integrins, receptors which are main regulators for the proper cell adhesion [99] . The integrin expression activates the lung cancer-related V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/v-rel avian reticuloendotheliosis viral oncogene homolog B/ nucreal factor-kB pathway and leads to stem celllike properties such as anchorage independent growth, tumor progression and drug resistance. Because of their function to create and maintain the communication between the ECM, inflammatory cells, fibroblasts and parenchymal cells, the integrins play not just a huge role in cancer, but also in IPF. They are involved in the processes of initiation, maintenance and resolution of tissue fibrosis. High expression of integrins was observed in myofibroblasts and in alveolar epithelial cells (AECs) after lung injury compared to untreated controls. It was also demonstrated that integrins are strong regulators of TGF-ß during lung fibrosis. The integrin family is therefore an interesting target for treatment of IPF. Different inhibitors are in preclinical and clinical phases, for example specific antibodies against avb6. Different kinds of these antibodies were tested in preclinical models of fibrosis among others bleomycin -models in mice. There is already one humanized antibody STX-100 in clinical trial phase 2 for treatment of IPF [100] . The parallels of IPF and cancer concerning the aspects of migration could help finding therapeutic targets for both diseases.
INFLAMMATION
Although the role of inflammation in IPF has been a contradiction, its participation as a promoting factor in the development and progression of tumorigenesis is frequently described [101] . Myeloidderived suppressor cells are associated with poor prognosis in malignancies and their expansion and accumulation in IPF is also correlated with disease progression [102] . Moreover, pulmonary fibrosis is characterized by the complex interaction with cells that are also involved in chronic inflammation. Overexpression of chemokines like CCL8 that attract monocytes has been recently associated with the disease [103] . Fibrosis-associated macrophages display an M2 phenotype, best characterized by strong expression of arginase, chitinaselike molecules, resistin-like molecule a and CD206 [104] . They facilitate the enhanced production of FGFs [105] , profibrotic cytokines [106, 107] and matrix metalloproteinases [108] . Their ablation by liposomal clodronate, or deletion of C-C-motif chemokine receptor 2 or plasminogen activator inhibitor-1 protects against lung fibrogenesis [107, 109, 110] .
MESENCHYMAL FEATURES OF LUNG CANCER CELLS
Mesenchymal cells are not only critical for lung development and fibrosis, but also for tumorigenesis [111, 112] . Stromal fibroblasts can effect tumor cell behavior in various manners. For instance, fibroblasts of the host environment interact with tumor cells and secrete in the ECM several growth factors like TGF-b, which next enhance a metastatic profile [113, 114] . Moreover, tumor-associated fibroblasts regulate matrix stiffness and, thereby, tumor cells promote angiogenesis [115, 116] . They also produce fibroblast activation protein, a serine peptidase that has been associated with lymph node metastasis and overall poor prognosis [117, 118] . In addition, while tumorigenesis is in progress, fibroblasts induce a pretumoral phenotype of tumor-associated macrophages, which plays a pivotal role in the immunosuppression induced within the tumor microenvironment [119] .
EPITHELIAL-MESENCHYMAL TRANSITION
Epithelial-mesenchymal transformation (or transition; EMT) is a process of multiple phenotypic transitions including shape changes towards elongated and spindle-shaped cellular morphology, enhanced cytoplasmic cytoskeletal protein expression and activity and the capacity for anchorageindependent growth, motility, migration and invasion, as well as an increased resistance to apoptosis [116, 120, 121] . This epithelial-mesenchymal phenotypic transition has been clearly observed during the malignant transformation of respiratory epithelial cells, and this link is supported by evidence suggesting that the same oncoproteins that drive lung cancer formation and progression (i.e. mutant KRAS) are responsible for EMT [122, 123] . It is clear that EMT with its ability to invade contributes to metastasis, and together with therapeutic resistance plays a major role in tumorigenesis [121] . EMT is induced by multiple pathways such as winglesstype, receptor tyrosine kinase (RTK) and TGF-ß signaling, which are controlled by genetic and epigenetic mechanisms. In a tumor, the cells are heterogenic populations created by instability of these processes. A major player in EMT is the NF-kB pathway, which can be activated by Notch, RTKs or KRAS [121-123,124 && ]. Compared with the strong evidence of the major role of EMT in cancer development, it is controversially discussed whether 'true' EMT contributes to lung fibrogenesis [116, [125] [126] [127] [128] . Although some may consider EMT to be partial or incomplete in pulmonary fibrosis, abundant evidence supports the plasticity of alveolar epithelial cells that can, in the context of lung injury, acquire a number of mesenchymal-like phenotypic behaviors [127, [129] [130] [131] [132] . This phenotypic transition is not limited to fibrotic lung injury, as airway epithelial cells were recently shown to migrate distally in response to influenza H1N1 infection of mice, thereby acquiring fibroblast phenotypes [133 && ]. Unpublished observations from our laboratories indicate that similar processes occur both after tobacco smoke-contained carcinogen exposure and after bleomycin-induced lung injury and fibrosis [133 && ,134]. In bleomycin-induced lung fibrosis, it was shown that pleural mesothelial cells start expressing an EMT phenotype with increased mesenchymal phenotypic markers and decreased epithelial phenotypic markers, as well as higher collagen-I synthesis, cell migration and activated TGF-ß1-Smad2/3 signaling pathway [135] . EMT in AECs was already proven over 10 years ago in primary cell culture, tissue samples of IPF patients, as well as mouse models. A main driving power and mediator thereby was TGF-ß. Multiple researchers could show the cell-type transition by increases in typical mesenchymal markers such as a-smooth muscle actin or vimentin and decreases in epithelial markers thyroid transcription factor-cadherin, e-cadherin and prosurfactant protein-B in these samples [136] [137] [138] . Even so, EMT is a common event in both IPF and cancer. In IPF, mesothelial cells can also undergo transition to mesenchymal cells, a process called mesothelial-to-mesenchymal transition (MMT). After breakdown of healthy repair and regulatory pathways, mesothelial cells can in this way contribute to the development of tissue fibrosis. By lineage tracing of mesothelial cells in mice, the EMT process was observed during development and was then named MMT. Later, MMT was observed in mesothelial cells after exposure to different kinds of toxic agents, as well as TGF-ß. The TGF-ß-treated mouse models underwent MMT and a transition from mesothelial cells to myofibroblasts resulting in fibrosis [139] . Principal in both cancer and IPF, the typical process of EMT with loss of cellular contacts, epithelial cell morphology and polarity has a net negative outcome in disease progression.
STEM CELLS
A cancer stem cell (CSC) is defined as that part of tumor which can constantly provide new cancer cells and also mobilize noncancer cells, such as mesenchymal and vascular cells. This group of cells shows increased telomere length controlled by highly active telomerase, has more active antiapoptotic pathways, and has a high activity of membrane transporters like ABC transporters, which can pump given drugs out of the cell [140] [141] [142] . The ABCG2 gene for instance is overexpressed in lung CSCs and serves as a typical marker for this cell type [143] . In IPF, similar mechanisms are involved. The ABCA3 gene, another member of the ABC transporter superfamily, is widely mutated in lung diseases and responsible for an abnormal surfactant metabolism and maybe a risk factor for IPF [144] . Taken together, in both lung diseases, the typical features of stem cell-like behavior play a major role in the pathogenesis, but instead of overlapping mechanisms they have a more opposite outcome. Having this in mind, it is not surprising that the therapeutic approaches are different. It is clear that CSCs have a negative impact in cancer progression and drug resistance and need to be targeted. In IPF, drug development focuses on mesenchymal stem cells (MSCs), a side population of stem cells originated from nonhematopoietic cells. These cells play significant roles in inhibition of T-cell proliferation and in secreting anti-inflammatory cytokines and growth factors, thus becoming a potential therapeutic target. Instead of the idea to inhibit the stem cell-like cell population in cancer therapy, researchers try to use the protective and repairative effects of the MSCs to treat IPF. After positive results in mouse experiments, several clinical trials with MSCs in the treatment of IPF are ongoing [145] .
IDIOPATHIC PULMONARY FIBROSIS SIGNALING PATHWAYS PROMOTING CANCER
Several studies demonstrate different signaling pathways that are strictly associated with fibroblasts and also play key roles in tumorigenesis. For instance, PI3K-Akt signaling substrate Girdin, an actin-binding protein that regulates cell migration, is expressed and activated by Akt phosphorylation in cancer-associated fibroblasts, thus promoting lung tumor progression [146] . Furthermore, the tumor microenvironment expresses survival and progression factors, which undergo a regulatory mechanism by the action of the mitogen-activated protein kinase 38 (p38MAPK) [147] . p38MAPK-leads in a hyaluronan-dependent reprogramming of the tumor microenvironment that promotes lung cancer growth [148] . Interestingly, STAT3 phosphorylation and induction of antiapoptotic protein Bcl-2 and Survivin in lung cancer cells was found after cisplatin fibroblast stimulation and upregulation of IL-11. This effect confers lung cancer cells the advantage of chemoresistance [149] . S100A4, a fibroblast marker and activator of fibroblast-specific transcriptional programs, has been shown to be expressed in IPF and to protect from metastasis [150] . FGF and TGF signaling in lung tumor cells, or mutations in their receptors, have been shown to be essential for lung adenocarcinoma development [151] [152] [153] . It is obvious that signaling pathways that are critical for fibrosis progression are also sensibly promoting tumor expansion and migration.
CONCLUSION
Cancer and fibrosis are two discernible lung diseases that are impressively characterized and driven by similar biological pathways. Although their specific genetic and cellular mechanisms are not yet fully defined, several signaling pathways, anatomical compartments and the microenvironmental behavior corrupt tissue architecture and lead to its dysfunction [154, 155] . However, it is clear that lung tumorigenesis and fibrosis display a highly heterogeneous behavior, which raises the need for a more personalized therapeutic approach [156] [157] [158] [159] . Attenuation of lung fibrosis can be served by focusing on and exploring these overlapping mechanisms.
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